Effect of CMI on Actuarial Survival and DFS in ML Patients who Received Immunotherapy Versus Historical Controls
| . | CMI . | Survival: Follow-Up Range (mo) . | No. of Patients . | P . | DFS: No. of Patients . | P . |
|---|---|---|---|---|---|---|
| HD | + | (8-78) | 24/24 | .02 | 21/24 | .042 |
| − | (8-84) | 17/25 | 17/25 | |||
| NHL | + | (7-78) | 29/32 | .01 | 24/32 | .01 |
| − | (5-84) | 18/36 | 15/36 | |||
| ML | + | (7-78) | 53/56 | .01 | 45/56 | .01 |
| − | (5/84) | 35/61 | 32/61 |
| . | CMI . | Survival: Follow-Up Range (mo) . | No. of Patients . | P . | DFS: No. of Patients . | P . |
|---|---|---|---|---|---|---|
| HD | + | (8-78) | 24/24 | .02 | 21/24 | .042 |
| − | (8-84) | 17/25 | 17/25 | |||
| NHL | + | (7-78) | 29/32 | .01 | 24/32 | .01 |
| − | (5-84) | 18/36 | 15/36 | |||
| ML | + | (7-78) | 53/56 | .01 | 45/56 | .01 |
| − | (5/84) | 35/61 | 32/61 |